The CTSI Transformative Funding Agreement provides funding up to $500,000 to address the T1 valley of death: the gulf between novel clinically motivated research and products that show safety and efficacy in humans (Coller BS and Califf RM, 2009). This program seeks to provide funding for development of mature research that if successful will attract significant interest for external partnering. The goal of this program is to enable and accelerate translation of research out of the academic environment (i.e. new company formation, license, or partnership).
Applicants will work toward major milestones (e.g. prototype development, GMP manufacture, GLP toxicology studies, IND submission, completion of Phase I clinical trial) that will enable this translation. Projects selected for funding will be assigned a translational support team for a run-in period of up to six months to deliver a proposed development path, outsourcing plan, and detailed project timeline before funds are released.
Examples of projects responsive to this application might include, but are not limited to, the following:
- A therapeutic agent that has shown efficacy in animal models but needs funding to complete scale up, pharm/tox studies and submit IND needed for clinical trials.
- An alpha prototype device with early proof-of-concept data that needs funding to manufacture devices and conduct clinical trials.
Teams are encouraged to identify areas in the application where students or trainees may be engaged as part of the research team.
Deadlines:
- Letter of Intent (Optional): August 20, 2019
- Application Submission Deadline: September 5, 2019